Hikal

Which are the latest news on Hikal?

Why is Hikal Ltd falling/rising?

As of 20-Jun, Hikal Ltd's stock price is rising to 205.25, reflecting a 3.4% increase. This growth is driven by strong investor interest, significant profit improvements, and increased trading activity, despite long-term challenges.

As of 20-Jun, Hikal Ltd's stock price is rising, currently at 205.25, reflecting a change of 6.75 or 3.4% increase. This upward movement can be attributed to several factors. The stock has been on a positive trajectory, gaining for the last six days and achieving a total return of 17.32% during this period. Additionally, it has outperformed its sector by 2.68% today. The stock also reached an intraday high of Rs 209.7, indicating strong investor interest.<BR><BR>Investor participation has notably increased, with delivery volume on June 18 rising by 227.68% compared to the five-day average, suggesting heightened demand. Furthermore, the company's recent financial results have shown significant improvements, such as a 1345.9% growth in profit before tax compared to the previous four-quarter average and a low debt-equity ratio of 0.57 times, which enhances its financial stability.<BR><BR>Despite the stock's long-term challenges, including a -42.67% return over the past year and a weak long-term fundamental strength, the current momentum appears to be driven by short-term positive performance indicators and increased trading activity.

Should I buy, sell or hold Hikal Ltd?

How big is Hikal?

As of 10th June, Hikal Ltd has a market capitalization of 2,232.00 Cr, with recent net sales of 1,712.60 Cr and a net profit loss of 48.80 Cr over the last four quarters. Shareholder's funds are 1,262.30 Cr, and total assets are valued at 2,528.90 Cr.

As of 10th June, <BR><BR>Market Cap: Hikal Ltd has a market capitalization of 2,232.00 Cr, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 1,712.60 Cr, while the sum of Net Profit for the same period shows a loss of 48.80 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the latest annual data is March 2025. Shareholder's Funds stand at 1,262.30 Cr, and Total Assets are valued at 2,528.90 Cr.

Who are in the management team of Hikal?

The management team of Hikal includes Jai Hiremath (Executive Chairman), Sameer Hiremath (Managing Director), and several non-executive and independent directors, such as Baba Kalyani and Kannan Unni, providing a blend of leadership and oversight.

The management team of Hikal includes the following key individuals:<BR><BR>1. **Jai Hiremath** - Executive Chairman<BR>2. **Sameer Hiremath** - Managing Director<BR>3. **Baba Kalyani** - Non-Executive & Non-Independent Director<BR>4. **Kannan Unni** - Non-Executive & Independent Director<BR>5. **Sugandha Hiremath** - Non-Executive & Non-Independent Director<BR>6. **Prakash V Mehta** - Non-Executive & Independent Director<BR>7. **Amit B Kalyani** - Non-Executive & Non-Independent Director<BR>8. **Ranjit Shahani** - Non-Executive & Independent Director<BR>9. **Shivani Bhasin Sachdeva** - Non-Executive & Independent Director<BR>10. **Rajasekhar Reddy** - Company Secretary & Compliance Officer<BR>11. **Shrikrishna K. Adivarekar** - Independent Director<BR>12. **Berjis Minoo Desai** - Independent Director<BR>13. **V R Kaundinya** - Independent Director<BR><BR>This team brings a mix of executive leadership and independent oversight to the company.

Who are the peers of the Hikal?

Hikal's peers include Unichem Labs, Solara Active, Morepen Labs, Kwality Pharma, Venus Remedies, Indoco Remedies, NGL Fine Chem, Windlas Biotech, and Sakar Healthcare. Hikal has Below Average management risk and capital structure, with a 1-year return of -52.29%, the lowest among its peers.

Peers: The peers of Hikal are Unichem Labs., Solara Active, Morepen Labs., Kwality Pharma, Venus Remedies, Indoco Remedies, NGL Fine Chem, Windlas Biotech, and Sakar Healthcare.<BR><BR>Quality Snapshot: Excellent management risk is observed at Morepen Labs., Kwality Pharma, Venus Remedies, NGL Fine Chem, and Windlas Biotech, while Average management risk is found at Unichem Labs., Solara Active, Hikal, Indoco Remedies, and Sakar Healthcare. Below Average management risk is noted at Solara Active. Growth is categorized as Good for Unichem Labs. and Venus Remedies, while Below Average growth is seen at Solara Active, Morepen Labs., Kwality Pharma, Hikal, Indoco Remedies, and Windlas Biotech. Excellent capital structure is present in Morepen Labs., Kwality Pharma, Venus Remedies, NGL Fine Chem, and Windlas Biotech, while Hikal, Indoco Remedies, and Sakar Healthcare exhibit Below Average capital structure.<BR><BR>Return Snapshot: Venus Remedies has the highest 1-year return at 268.68%, while Hikal has the lowest at -52.29%. Hikal's 1-year return is significantly lower than all its peers. Additionally, Indoco Remedies and Windlas Biotech have negative six-month returns.

What does Hikal do?

Hikal Ltd is a small-cap company in the Pharmaceuticals & Biotechnology sector, specializing in chemical intermediates, specialty chemicals, and active pharma ingredients. As of March 2026, it reported net sales of 519 Cr and a net profit of 14 Cr, with a market cap of INR 2,232 Cr.

Overview:<BR>Hikal Ltd is a small-cap company in the Pharmaceuticals & Biotechnology industry, engaged in the manufacturing of chemical intermediates, specialty chemicals, active pharma ingredients, and contract research activities.<BR><BR>History:<BR>Hikal Limited was incorporated on July 8, 1988. The latest quarterly results reported net sales and profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 519 Cr (Quarterly Results - Mar 2026)<BR>- Net Profit: 14 Cr (Quarterly Results - Mar 2026)<BR>- Market cap: INR 2,232 Cr (Small Cap)<BR><BR>Key Metrics:<BR>- P/E: 61.00<BR>- Industry P/E: 34<BR>- Dividend Yield: 0.55%<BR>- Debt Equity: 0.56<BR>- Return on Equity: 3.03%<BR>- Price to Book: 1.87<BR><BR>Contact Details:<BR>Address: 717/718 Maker Chamber V, 7th Floor Nariman Point Mumbai Maharashtra : 400021<BR>Tel: 91-022-3926 7100/62770477<BR>Email: secretarial@hikal.com/info@hikal.co<BR>Website: http://www.hikal.com

Are Hikal Ltd latest results good or bad?

Hikal Ltd's latest results are largely negative, showing a 71.31% year-on-year decline in net profit and a 5.97% decrease in revenue, despite a modest quarter-on-quarter improvement. The company faces challenges, particularly in its crop protection segment, and its stock has underperformed significantly over the past year.

Hikal Ltd's latest results present a mixed picture, leaning towards the negative. In Q4 FY26, the company reported a net profit of ₹14.40 crores, which, while an improvement from a loss of ₹5.90 crores in the previous quarter, reflects a significant decline of 71.31% year-on-year from ₹50.20 crores. Revenue for the quarter was ₹519.40 crores, showing a modest quarter-on-quarter increase of 5.08% but a year-on-year decrease of 5.97%.<BR><BR>The operating margin improved to 20.39% from 16.85% in the previous quarter, but this is still down 204 basis points compared to the same quarter last year. Overall, the company is facing challenges, particularly in its crop protection segment, which has been affected by subdued global demand.<BR><BR>Additionally, Hikal's stock has underperformed significantly over the past year, declining by 40.92%, compared to a 6.97% fall in the Sensex. This underperformance raises concerns about the company's ability to navigate the current market conditions effectively.<BR><BR>In summary, while there are some signs of sequential recovery, the year-on-year declines in both profit and revenue, along with ongoing operational challenges, suggest that the latest results are not favorable overall.

When is the next results date for Hikal Ltd?

The next results date for Hikal Ltd is 27 May 2026.

The next results date for Hikal Ltd is scheduled for 27 May 2026.

Has Hikal Ltd declared dividend?

Yes, Hikal Ltd has declared a dividend of 10% (0.8 per share) with an ex-date of February 17, 2026. Despite the dividend, the company has experienced significant price declines over various periods, resulting in modest total returns.

Hikal Ltd has declared a dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 10%<BR>- Amount per share: 0.8<BR>- Ex-date: 17 Feb 26<BR><BR>Dividend Yield: 0.37%.<BR><BR>Total Returns by Period:<BR>In the last 3 months, Hikal Ltd experienced a price return of -11.18%, a dividend return of 0.08%, resulting in a total return of -11.1%.<BR><BR>Over the past 6 months, the company saw a price return of -16.63%, a dividend return of 0.39%, leading to a total return of -16.24%.<BR><BR>In the 1-year period, Hikal Ltd reported a price return of -39.05%, a dividend return of 0.29%, culminating in a total return of -38.76%.<BR><BR>For the 2-year period, the price return was -23.52%, with a dividend return of 0.78%, resulting in a total return of -22.74%.<BR><BR>In the 3-year timeframe, the company had a price return of -35.23%, a dividend return of 1.13%, which gave a total return of -34.1%.<BR><BR>Over the last 4 years, Hikal Ltd experienced a price return of -49.8%, a dividend return of 1.25%, leading to a total return of -48.55%.<BR><BR>Finally, in the 5-year period, the company achieved a price return of 27.87%, a dividend return of 4.15%, resulting in a total return of 32.02%.<BR><BR>Overall, while Hikal Ltd has declared a dividend, the total returns over various periods indicate significant price declines, particularly in the shorter terms, despite some recovery in the longer term. The dividend yield remains modest in comparison to the price performance.

Is Hikal overvalued or undervalued?

As of December 4, 2025, Hikal's valuation has shifted from attractive to fair, with a high PE ratio of 309.11 and significant underperformance at -35.04% year-to-date, indicating concerns about its growth prospects compared to peers like Sun Pharma and Cipla.

As of 4 December 2025, Hikal's valuation grade has moved from attractive to fair, indicating a shift in its perceived value. The company is currently fairly valued, with a PE ratio of 309.11, an EV to EBITDA of 16.62, and a Price to Book Value of 2.61. In comparison to peers, Sun Pharma has a PE ratio of 37.78 and an EV to EBITDA of 24.99, while Cipla is rated attractive with a PE of 22.58 and an EV to EBITDA of 15.98, highlighting Hikal's significant overvaluation relative to its competitors.<BR><BR>Despite its fair valuation, Hikal has underperformed in the market, with a year-to-date return of -35.04% compared to the Sensex's 9.12%. This underperformance, coupled with a high PEG ratio of 0.00 and low ROE of 0.85%, suggests that investors may be cautious about the company's growth prospects moving forward.

Is Hikal technically bullish or bearish?

As of December 3, 2025, Hikal's technical trend is mildly bearish, with mixed signals from indicators like the MACD and Bollinger Bands, suggesting a cautious outlook in the short term.

As of 3 December 2025, the technical trend for Hikal has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by several key indicators. The weekly MACD is mildly bullish, but the monthly MACD remains bearish, indicating mixed signals. The Bollinger Bands and moving averages are both mildly bearish on the weekly and daily time frames. The KST shows a mildly bullish signal on the weekly, while the monthly remains bearish. The Dow Theory also reflects a mildly bullish stance on the weekly but is bearish on the monthly. Overall, the indicators suggest a cautious outlook with a slight bearish bias in the short term.

How has been the historical performance of Hikal?

Hikal's historical performance shows mixed results, with net sales peaking at 2,023.03 Cr in Mar'23 before declining to 1,859.80 Cr in Mar'25, while operating profit increased slightly to 333.40 Cr in Mar'25, despite decreases in profit before and after tax. Total assets and liabilities rose to 2,528.90 Cr in Mar'25, and cash flow from operating activities improved to 280.00 Cr.

Answer:<BR>The historical performance of Hikal shows a mixed trend in its financial metrics over the years.<BR><BR>Breakdown:<BR>Hikal's net sales have fluctuated, with a peak of 2,023.03 Cr in Mar'23, followed by a decline to 1,859.80 Cr in Mar'25. The total operating income mirrored this trend, reaching 2,023.03 Cr in Mar'23 and decreasing to 1,859.80 Cr in Mar'25. Raw material costs rose to 882.60 Cr in Mar'25 from 781.90 Cr in Mar'20, while total expenditure (excluding depreciation) decreased to 1,531.40 Cr in Mar'25 from 1,765.96 Cr in Mar'23. Operating profit (PBDIT) saw a slight increase to 333.40 Cr in Mar'25 from 262.48 Cr in Mar'23, although profit before tax dropped to 123.80 Cr in Mar'25 from 105.37 Cr in Mar'23. Profit after tax also decreased to 90.80 Cr in Mar'25 from 78.39 Cr in Mar'23. The company's total assets increased to 2,528.90 Cr in Mar'25 from 2,385.48 Cr in Mar'23, while total liabilities rose to 2,528.90 Cr in Mar'25 from 2,385.48 Cr in Mar'23. Cash flow from operating activities improved to 280.00 Cr in Mar'25 from 186.00 Cr in Mar'24, indicating a positive trend in cash generation. Overall, Hikal's financial performance reflects both challenges and improvements across various metrics over the years.

Who are the top shareholders of the Hikal?

The top shareholders of Hikal include Kalyani Investment Company Limited with 31.36%, followed by 76 Foreign Institutional Investors holding 5.69%, and mutual funds with a combined 2.93%. Individual investors own 16.57%, with Tata Mutual Fund - Tata Small Cap Fund being the largest public shareholder at 2.68%.

The top shareholders of Hikal include the promoters, who hold the majority of the shares. The promoter with the highest holding is Kalyani Investment Company Limited, which owns 31.36% of the company. Additionally, there are 76 Foreign Institutional Investors (FIIs) holding 5.69%, and mutual funds are represented by 7 schemes with a combined holding of 2.93%. The highest public shareholder is Tata Mutual Fund - Tata Small Cap Fund, which holds 2.68%. Individual investors collectively own 16.57% of the shares.

What is the bonus history of the Hikal?

Hikal Ltd announced a 1:2 bonus issue on June 22, 2018, with a record date of June 25, 2018, meaning shareholders received one additional share for every two shares held.

Hikal Ltd has a bonus history that includes a 1:2 bonus issue announced on June 22, 2018. The record date for this bonus was June 25, 2018. This means that for every two shares held, shareholders received one additional share as a bonus.